Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAL-1 Gene Therapy for HIV-Associated Lymphoma
NCT02378922Phase 1Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2016
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cal-1 in HIV-associated lymphoma and human immunodeficiency virus infection (HIV), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Feasibility of collection of >= 2.1 x 10^6 CD34+ cells/kg at 15 years, Feasibility of genetic modification at 15 years and 6 more. Planned start Jun 2016; status: withdrawn.
02
Drugs
Cal-1
03
Conditions
HIV-associated lymphomahuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02378922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378922.